Biogen Resolves Multiple Sclerosis Drug Dispute
Shares of Biogen were lower Tuesday after the company resolved a dispute with Forward Pharma over its multiple sclerosis drug.
Shares of Biogen (BIIB) - Get Report were lower Tuesday after the company resolved a dispute with Forward Pharma (FWP) - Get Report over its multiple sclerosis drug. Biogen agreed to pay Forward $1.25 billion, which will give it a license to all intellectual property owned by Forward. Under the agreement, Biogen will also have to pay the Denmark-based company royalties of 10% to 20% of net sales of Biogen products approved for the treatment of multiple sclerosis.
Employees of TheStreet are restricted from trading individual securities.
